Dr Reddy’s Laboratories introduces COVID-19 drug 2-DG for sale in the market

Drug manufacturer Dr. Reddy’s Laboratories on Monday announced the commercial launch of 2-DG, a drug useful in the treatment of Covid-19. The company has fixed the maximum retail price of this drug at Rs 990 per sachet. Dr. Reddy’s in his statement said that the company will make available the 2DG drug in all major government hospitals as well as private hospitals across India.

The company said that in the initial week, the company will make this drug available in hospitals in all metros and tier-1 cities and thereafter its availability will be ensured across the country. The purity of this drug manufactured by the company is 99.5 percent and it will be sold under the name of 2DG.

Dr. Reddy’s Chairman Satheesh Reddy said that 2DG is another product in our COVID-19 portfolio. It gives us immense pleasure to partner with DRDO in the collective fight against the COVID-19 pandemic. Dr. Reddy’s said that this drug can be used only on moderately severe COVID-19 patients admitted to the hospital under medical advice and supervision of a qualified medical practitioner.

Approval for emergency use of this anti-COVID-19 therapeutic drug was given on May 1, 2021. 2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defense Research and Development Organization, in collaboration with Dr. Reddy’s Laboratories.